Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie the best
available examples of the humoral immune response to HIV are providing important …

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups.
Binding but non-neutralizing responses are directed to epitopes that are expressed on …

Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …

Antibodies with ontogenies from VH 1-2 or VH 1-46-germline genes dominate the broadly
neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with …

The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by
broadly reactive antibodies, several of which neutralize over 90% of HIV-1 strains. To …